ClinicalTrials.gg
Not yet recruitingNCT07585071Updated Nov 5, 2026

IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia

A Phase 1 interventional study of IASO206 injection in Autoimmune Hemolytic Anemia and Relapsed/Refractory, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 1, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Anemia, Hemolytic, Autoimmune by Institute of Hematology & Blood Diseases Hospital, China — 8 open to participants now, 12 under way, none of them phase 3. Anemia, Hemolytic, Autoimmune · Institute of Hematology & Blood Diseases Hospital, China.

Planned enrollment
3rd of 11
18 · median 12
Started
2026
with 2 others
Phase 1
8 of 15
3 open now
Primary completion
2027-12
later than 6 of 11 live
Registered
13th of 15
by date

Among the 15 studies in Anemia, Hemolytic, Autoimmune by Institute of Hematology & Blood Diseases Hospital, China, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 6 of the 11 other live ones, and was the 13th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

8 of the 15 studies in Anemia, Hemolytic, Autoimmune by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Anemia, Hemolytic, Autoimmune by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection (In Vivo CAR-T) in Patients with Relapsed/Refractory Autoimmune Hemolytic Anemia

03

Conditions studied

  • Autoimmune Hemolytic Anemia
  • Relapsed/Refractory
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years, gender unrestricted.
  • Diagnosis of AIHA (including warm antibody type, warm-cold antibody type, cold agglutinin disease) or Evans syndrome, consistent with Chinese Expert Consensus on Diagnosis and Treatment of Hemolytic Anemia (2023), 2019 International Consensus for Diagnosis and Management of Autoimmune Hemolytic Anemia (Blood Rev, 2020), or Chinese Expert Consensus on Diagnosis and Treatment of Evans Syndrome (2024 Edition).
  • Patients with disease after multiple must meet all of the following criteria: \< 10 g/dL with clinical manifestations of hemolytic anemia; prior treatment with at least 2 drugs (must include CD20 monoclonal antibody); therapy for at least 3 months (excluded are patients with to glucocorticoids, severe infection, severe osteoporosis, previous fracture, or inability to tolerate glucocorticoids); cumulative dose of CD20 monoclonal antibody at least 375 mg/m² × 4, or total dose 2.0 g, or at least 6 administrations (at least 1 week apart each time).
  • score ≤ 2.
  • Expected survival time ≥ 12 weeks.
  • Adequate organ function confirmed by laboratory tests: serum (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × (ULN); minimum pulmonary reserve defined as grade ≤ 1 dyspnea and oxygen saturation ≥ 93% without oxygen supplementation; (estimated by Cockcroft-Gault) ≥ 45 mL/min; cardiac ≥ 50%, no pericardial effusion on echocardiogram (ECHO), and no abnormal (ECG).
  • Subjects and their partners agree to use effective barrier or medical measures (excluding rhythm method) from signing until 1 year after administration.
  • Subjects must provide written informed consent approved by the Ethics Committee prior to initiation of screening procedures

Exclusion criteria

Exclusion Criteria:

  • Subject with confirmed lymphoproliferative neoplasms.
  • Subject with secondary AIHA induced by drugs or infection.
  • Subject with congenital immunodeficiency diseases, other hereditary or acquired hemolytic diseases.
  • Subject with a history of organ or stem cell transplantation.
  • Subject with a history of organ infarction within the past 6 months.
  • Subject who have received prior BCMA-targeted therapy.
  • Subject who received plasma cell-targeted cell therapy within 3 months before screening, or in whom prior cell therapy products are still detectable in peripheral blood.
  • Subject who received any of the following treatments within the specified periods prior to study enrollment:

    1. Anti-CD20 monoclonal antibody \< 12 weeks;
    2. Sutimlimab or other marketed biological products \< 5 half-lives;
    3. Plasma exchange \< 4 weeks;
    4. Splenectomy \< 12 weeks.
  • Subject with any of the following cardiovascular diseases:

    1. (LVEF) ≤ 45%;
    2. Active heart disease or congestive heart failure ( [NYHA] Class III or IV);
    3. Severe arrhythmia requiring treatment (excluding atrial fibrillation, paroxysmal supraventricular tachycardia);
    4. interval ≥ 450 ms for males, ≥ 470 ms for females;
    5. Myocardial infarction, bypass surgery, or stent implantation within 6 months before study;
    6. Other cardiac diseases judged by the investigator to be unsuitable for enrollment.
  • Unstable systemic diseases judged by the investigator, including but not limited to severe hepatic or renal diseases requiring medical treatment.
  • Subject with a history of other primary within 5 years before screening, except:

    1. Resected and cured non-melanoma skin cancer (e.g., basal cell carcinoma);
    2. Cured carcinoma in situ (e.g., cervical, bladder, or breast cancer);
    3. Other primary cancers with no evidence of recurrence for more than 5 years after treatment.
  • Subject who underwent major surgery within 4 weeks before screening and are judged unsuitable for enrollment by the investigator.
  • Subject with uncontrolled active fungal, viral, bacterial, mycobacterial, or other infections (persistent infection-related signs/symptoms without improvement after appropriate anti-infective therapy) or infections requiring intravenous anti-infective therapy.
  • Positive surface antigen (HBs-Ag) or hepatitis B e antigen (HBe-Ag); positive hepatitis B e antibody (HBe-Ab) or hepatitis B core antibody (HBc-Ab) with HBV-DNA copy number above the lower limit of quantification; positive (HCV) antibody; positive (HIV) antibody; active syphilis infection (excluding those with only positive syphilis-specific antibody).
  • Subject who received live viral vaccines within 4 weeks before enrollment.
  • Subject who are participating in other interventional clinical studies during IASO206 Injection treatment with a drug half-life \< 5; subject receiving active drugs during the entire study period, or who intend to participate in another clinical trial, or receive treatments outside the protocol.
  • Pregnant or lactating females.
  • Subject with psychiatric disorders, disturbance of consciousness, or central nervous system diseases, including but not limited to epilepsy and Parkinson's disease.
  • Subject with to components of IASO206 Injection or supportive medications required for the management of CAR-T therapy-related toxicities (e.g., tocilizumab).
  • Other conditions judged by the investigator to be unsuitable for enrollment.10. Other Information
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    IASO206

    Subjects will receive a single infusion of IASO206 injection in a 3+3 dose-escalation design. Three ascending dose cohorts are planned: 1E8 TU, 3E8 TU, and 5E8 TU. In each dose cohort, the first subject will be observed for at least 3 weeks after infusion before subsequent subjects in the same cohort receive IASO206 injection.

    Biological: IASO206 injection

Interventions

  • BiologicalIASO206 injection

    The third-generation self-inactivating lentiviral vector that carries a BCMA-targeted CAR. Administered in one infusion.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Assessed by CTCAE Version 5.0.

    Time frame: Up to 3 months after IASO206 infusion

Secondary outcomes

  1. Proportion of patients achieving response

    Response assessment is primarily assessed based on hemoglobin, and should be performed after discontinuation of glucocorticoids or other immunosuppressive therapies for at least 2 weeks.

    Time frame: At Weeks 4, 8, and 12, and Months 4, 5, and 6 after IASO206 infusion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Jun 2026 → Dec 2026 and primary completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 13, 2026
StartEst.
Dec 15, 2026was Jun 2026
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 15, 2026→Dec 15, 2026
Nov 5, 2026
Primary completion
Dec 31, 2026→Dec 31, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Jun 15, 2026→Dec 15, 2026
    Primary completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07585071
Responsible party
Jun Shi (Director of the Red Blood Cell Diseases Center & Director of the Regenerative Medicine Clinic, Institute of Hematology & Blood Diseases Hospital, China) — Principal investigator
First posted
May 13, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Jun Shi, PhD
Contact
shijun@ihcams.ac.cn
13752253515
Lele Zhang, PhD
Contact
zhanglele@ihcams.ac.cn
‭15811139278‬

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion